Comparative Pharmacology
Head-to-head clinical analysis: CIS MDP versus TECHNETIUM TC99M MERTIATIDE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIS MDP versus TECHNETIUM TC99M MERTIATIDE KIT.
CIS-MDP vs TECHNETIUM TC99M MERTIATIDE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CIS-MDP (cisplatin) is a platinum-containing antineoplastic agent that forms intrastrand and interstrand DNA crosslinks, inhibiting DNA replication and transcription through binding to purine bases.
Technetium Tc99m mertiatide is a radiopharmaceutical that undergoes renal tubular secretion and glomerular filtration, allowing imaging of the kidneys. After intravenous administration, it is primarily taken up by the kidneys and excreted into the urine, providing visualization of renal perfusion and function.
20 mCi (740 MBq) intravenous injection for bone scintigraphy; imaging performed 2-4 hours post-injection.
1 mCi (37 MBq) intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; clinically relevant for imaging timing and clearance from blood pool.
Terminal elimination half-life: 1.5–2.1 hours (mean 1.8 h). Effective half-life with Tc-99m decay: physical half-life 6.02 h, biological half-life ~1.8 h, effective half-life ~1.4 h. Clinically, imaging completed within 30–60 min post-injection.
Renal: 85-95% of administered dose excreted unchanged in urine within 24 hours; biliary/fecal: <5% eliminated via feces.
Renal: >90% of injected dose excreted via glomerular filtration and tubular secretion within 24 hours. Biliary/fecal: <1%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical